Cannabinoids have complex effects on kidneys, with synthetic versions posing the greatest danger
Natural cannabinoids show potential for nephroprotection through CB2 receptor activation and may help prevent kidney stones, while synthetic cannabinoids are strongly linked to acute kidney injury.
Quick Facts
What This Study Found
CB2 agonists showed therapeutic potential in diabetic nephropathy, chronic kidney disease, and obesity-related kidney dysfunction. CB1 antagonists also showed benefits. Cannabinoids may have diuretic and anti-inflammatory effects that reduce kidney stone risk. However, synthetic cannabinoids are strongly associated with acute kidney injury. Cannabinoid hyperemesis syndrome can also cause kidney damage through ischemia-reperfusion injury.
Key Numbers
CB1 and CB2 receptor roles examined across diabetic nephropathy, CKD, and obesity-related kidney dysfunction. Synthetic cannabinoids linked to acute kidney injury. Potential diuretic and anti-inflammatory effects for kidney stone prevention.
How They Did This
Narrative review examining cannabinoid receptor roles in kidney physiology, the effects of natural and synthetic cannabinoids on renal function, and the therapeutic potential and risks across multiple kidney conditions.
Why This Research Matters
Kidney health is rarely discussed in cannabis contexts, but millions of people with chronic kidney disease or diabetes-related kidney problems may benefit from targeted cannabinoid therapies, while synthetic cannabinoid users face serious renal risks.
The Bigger Picture
The divergent kidney effects of natural versus synthetic cannabinoids highlight a critical distinction that public health messaging often misses. As synthetic cannabinoid use persists in populations avoiding drug testing, the acute kidney injury risk remains an underrecognized harm.
What This Study Doesn't Tell Us
Narrative review with selective evidence synthesis. Most kidney-specific cannabinoid research is preclinical. Clinical evidence for nephroprotection is limited. The review covers a very broad range of conditions, limiting depth on any single topic.
Questions This Raises
- ?Could CB2-selective agonists become a treatment option for diabetic kidney disease?
- ?Should kidney function monitoring be standard for chronic cannabis users, especially those using synthetic products?
Trust & Context
- Key Stat:
- synthetic cannabinoids strongly associated with acute kidney injury, contrasting with potential nephroprotective effects of natural cannabinoids through CB2 receptors
- Evidence Grade:
- Comprehensive review spanning multiple kidney conditions, but mostly preclinical evidence. The synthetic cannabinoid-AKI link has stronger clinical support.
- Study Age:
- 2024 publication.
- Original Title:
- Renal Outcomes and Other Adverse Effects of Cannabinoid Supplementation.
- Published In:
- Nutrients, 17(1) (2024)
- Authors:
- Młynarska, Ewelina, Kustosik, Natalia, Mejza, Maja, Łysoń, Zuzanna, Delebis, Dawid, Orliński, Jakub, Rysz, Jacek, Franczyk, Beata
- Database ID:
- RTHC-05558
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Can cannabis damage your kidneys?
It depends on the type. Synthetic cannabinoids (like K2/Spice) are strongly linked to acute kidney injury. Natural cannabis has not been consistently linked to kidney damage, and some cannabinoid compounds show potential kidney-protective effects in preclinical studies.
How might cannabinoids help prevent kidney stones?
The review suggests cannabinoids may have diuretic effects (increasing urine flow) and anti-inflammatory properties that could reduce crystal retention in the kidneys, lowering stone formation risk. This is based on preclinical evidence and needs clinical confirmation.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05558APA
Młynarska, Ewelina; Kustosik, Natalia; Mejza, Maja; Łysoń, Zuzanna; Delebis, Dawid; Orliński, Jakub; Rysz, Jacek; Franczyk, Beata. (2024). Renal Outcomes and Other Adverse Effects of Cannabinoid Supplementation.. Nutrients, 17(1). https://doi.org/10.3390/nu17010059
MLA
Młynarska, Ewelina, et al. "Renal Outcomes and Other Adverse Effects of Cannabinoid Supplementation.." Nutrients, 2024. https://doi.org/10.3390/nu17010059
RethinkTHC
RethinkTHC Research Database. "Renal Outcomes and Other Adverse Effects of Cannabinoid Supp..." RTHC-05558. Retrieved from https://rethinkthc.com/research/mlynarska-2024-renal-outcomes-and-other
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.